vs
Finward Bancorp（FNWD）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Finward Bancorp的1.8倍（$30.3M vs $16.5M），Finward Bancorp净利率更高（12.0% vs -221.3%，领先233.4%），REGENXBIO Inc.同比增速更快（43.0% vs 1.1%），Finward Bancorp自由现金流更多（$9.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -19.1%）
Finward Bancorp是一家总部位于美国的区域性银行控股公司，主要面向本土运营区域内的个人消费者与中小企业，提供储蓄账户、各类贷款、商业融资及财富管理等零售与商业金融服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FNWD vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.8倍
$16.5M
营收增速更快
RGNX
高出41.9%
1.1%
净利率更高
FNWD
高出233.4%
-221.3%
自由现金流更多
FNWD
多$61.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-19.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.5M | $30.3M |
| 净利润 | $2.0M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 11.0% | -190.0% |
| 净利率 | 12.0% | -221.3% |
| 营收同比 | 1.1% | 43.0% |
| 净利润同比 | -5.6% | -31.2% |
| 每股收益（稀释后） | $0.46 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNWDRGNX
| Q4 25 | $16.5M | $30.3M | ||
| Q3 25 | $17.4M | $29.7M | ||
| Q2 25 | $16.6M | $21.4M | ||
| Q1 25 | $15.5M | $89.0M | ||
| Q4 24 | $16.3M | $21.2M | ||
| Q3 24 | $14.9M | $24.2M | ||
| Q2 24 | $14.6M | $22.3M | ||
| Q1 24 | $25.3M | $15.6M |
净利润FNWDRGNX
| Q4 25 | $2.0M | $-67.1M | ||
| Q3 25 | $3.5M | $-61.9M | ||
| Q2 25 | $2.2M | $-70.9M | ||
| Q1 25 | $455.0K | $6.1M | ||
| Q4 24 | $2.1M | $-51.2M | ||
| Q3 24 | $606.0K | $-59.6M | ||
| Q2 24 | $143.0K | $-53.0M | ||
| Q1 24 | $9.3M | $-63.3M |
毛利率FNWDRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FNWDRGNX
| Q4 25 | 11.0% | -190.0% | ||
| Q3 25 | 20.5% | -176.3% | ||
| Q2 25 | 12.7% | -296.3% | ||
| Q1 25 | 4.0% | 13.6% | ||
| Q4 24 | 16.3% | -242.1% | ||
| Q3 24 | 2.7% | -256.6% | ||
| Q2 24 | 0.9% | -251.3% | ||
| Q1 24 | 40.6% | -408.8% |
净利率FNWDRGNX
| Q4 25 | 12.0% | -221.3% | ||
| Q3 25 | 20.1% | -208.3% | ||
| Q2 25 | 12.9% | -331.8% | ||
| Q1 25 | 2.9% | 6.8% | ||
| Q4 24 | 12.9% | -241.3% | ||
| Q3 24 | 4.1% | -246.3% | ||
| Q2 24 | 1.0% | -237.7% | ||
| Q1 24 | 36.7% | -405.4% |
每股收益（稀释后）FNWDRGNX
| Q4 25 | $0.46 | $-1.30 | ||
| Q3 25 | $0.81 | $-1.20 | ||
| Q2 25 | $0.50 | $-1.38 | ||
| Q1 25 | $0.11 | $0.12 | ||
| Q4 24 | $0.50 | $-0.99 | ||
| Q3 24 | $0.14 | $-1.17 | ||
| Q2 24 | $0.03 | $-1.05 | ||
| Q1 24 | $2.17 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $174.7M | $102.7M |
| 总资产 | $2.0B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FNWDRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益FNWDRGNX
| Q4 25 | $174.7M | $102.7M | ||
| Q3 25 | $165.5M | $161.5M | ||
| Q2 25 | $154.3M | $213.7M | ||
| Q1 25 | $151.8M | $274.2M | ||
| Q4 24 | $151.4M | $259.7M | ||
| Q3 24 | $159.6M | $301.4M | ||
| Q2 24 | $148.6M | $348.3M | ||
| Q1 24 | $151.6M | $390.7M |
总资产FNWDRGNX
| Q4 25 | $2.0B | $453.0M | ||
| Q3 25 | $2.1B | $525.2M | ||
| Q2 25 | $2.1B | $581.0M | ||
| Q1 25 | $2.0B | $490.9M | ||
| Q4 24 | $2.1B | $466.0M | ||
| Q3 24 | $2.1B | $519.1M | ||
| Q2 24 | $2.1B | $569.4M | ||
| Q1 24 | $2.1B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $9.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 54.8% | -174.0% |
| 资本支出强度资本支出/营收 | 5.2% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.99× | — |
| 过去12个月自由现金流最近4个季度 | $10.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FNWDRGNX
| Q4 25 | $9.9M | $-52.3M | ||
| Q3 25 | $1.2M | $-56.0M | ||
| Q2 25 | $4.8M | $-49.3M | ||
| Q1 25 | $-3.8M | $33.6M | ||
| Q4 24 | $9.8M | $-31.6M | ||
| Q3 24 | $-3.7M | $-40.5M | ||
| Q2 24 | $2.8M | $-45.5M | ||
| Q1 24 | $-25.0K | $-55.5M |
自由现金流FNWDRGNX
| Q4 25 | $9.0M | $-52.8M | ||
| Q3 25 | $1.0M | $-56.5M | ||
| Q2 25 | $4.5M | $-49.7M | ||
| Q1 25 | $-4.0M | $32.6M | ||
| Q4 24 | $6.7M | $-32.7M | ||
| Q3 24 | $-4.2M | $-40.9M | ||
| Q2 24 | $1.1M | $-46.0M | ||
| Q1 24 | $-736.0K | $-56.0M |
自由现金流率FNWDRGNX
| Q4 25 | 54.8% | -174.0% | ||
| Q3 25 | 6.0% | -189.9% | ||
| Q2 25 | 27.0% | -232.8% | ||
| Q1 25 | -25.7% | 36.6% | ||
| Q4 24 | 41.2% | -154.2% | ||
| Q3 24 | -28.5% | -168.9% | ||
| Q2 24 | 7.6% | -206.2% | ||
| Q1 24 | -2.9% | -358.5% |
资本支出强度FNWDRGNX
| Q4 25 | 5.2% | 1.7% | ||
| Q3 25 | 0.9% | 1.7% | ||
| Q2 25 | 1.7% | 1.8% | ||
| Q1 25 | 1.2% | 1.2% | ||
| Q4 24 | 18.8% | 5.1% | ||
| Q3 24 | 3.4% | 1.3% | ||
| Q2 24 | 11.2% | 2.1% | ||
| Q1 24 | 2.8% | 3.6% |
现金转化率FNWDRGNX
| Q4 25 | 4.99× | — | ||
| Q3 25 | 0.34× | — | ||
| Q2 25 | 2.22× | — | ||
| Q1 25 | -8.37× | 5.53× | ||
| Q4 24 | 4.66× | — | ||
| Q3 24 | -6.15× | — | ||
| Q2 24 | 19.23× | — | ||
| Q1 24 | -0.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNWD
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
